Clinical Trials Browser

Recruiting × lenvatinib × 30 days × Clear all

NCT03486873 2026-06-05

MK-3475-587

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07405164 2026-05-29

MK-6482-043

Phase 3 Recruiting

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT05319730 2026-05-26

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07493668 2026-05-22

FLEX-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07594015 2026-05-18

Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy

Phase 2 Recruiting

Endometrial Neoplasms

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis